We are live on ! Find out more
RPRX icon

Repros Therapeutics
RPRX

Delisted

RPRX was delisted on the 31st of January, 2018.

56 hedge funds and large institutions have $12.3M invested in Repros Therapeutics in 2015 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more call options, than puts

Call options by funds: $564K | Put options by funds: $342K

3% less funds holding

Funds holding: 58 → 56 (-2)

15.72% less ownership

Funds ownership: 57.38% → 41.67% (-16%)

19% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 16

28% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 18

88% less capital inflows, than outflows

Capital inflows: $4.13M | Capital outflows: $34.8M

Holders
56
Holders Change
-2
Holders Change %
-3.45%
% of All Funds
1.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
13
Reduced
16
Closed
18
Calls
$564​K
Puts
$342​K
Net Calls
+$222​K
Net Calls Change
-⁠$9.09​M

RPRX Hedge Fund Activity: Q4 2015 in Review

56 of the 3,823 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics (RPRX) for Q4 2015, worth a combined $12.3M — down 88% from $104M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of RPRX and 13 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 13 added.

The largest buyer was Millennium Management, adding an estimated $1.17M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $14.5M sold.

  • 56 institutional investors held Repros Therapeutics (RPRX) as of Q4 2015, down from 58 in Q3 2015.
  • Funds reported $12.3M of Repros Therapeutics stock for Q4 2015, down 88% quarter-over-quarter.
  • 13 funds opened new Repros Therapeutics positions in Q4 2015 and 18 closed out, a net change of -5 holders.
  • The largest Repros Therapeutics buyer in Q4 2015 was Millennium Management, an estimated $1.17M added.
  • The largest Repros Therapeutics seller in Q4 2015 was Baker Bros. Advisors, an estimated $14.5M sold.

Based on aggregated 13F filings for Q4 2015.